Clinical trials: Rhinoconjunctivitis
Cat Allergy
Exposure Chamber Trial With Cat Immunotherapy
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
- Trial name
- NCT00987909
- Testing
- Specific allergen immunotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ALK-Abelló A/S
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting
- Trial name
- NCT00574704
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Volunteers
- 40 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.
Allergic rhinitis (AR) in its seasonal and perennial form is a common allergic condition. The majority of allergic rhinitis sufferers report nasal (congestion, sneezing, itching and rhinorrhea) and ocular (redness, watery eyes…
- Trial name
- NCT04532762
- Testing
- nasal spray
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Marinomed Biotech AG
Allergic Rhinoconjunctivitis
A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid
This is a research study of a vaccine for allergy to Japanese Red Cedar. The vaccine is called CryJ2-DNA-LAMP Plasmid vaccine. This research study will determine how the vaccine is tolerated and how research participants respond…
- Trial name
- NCT01707069
- Testing
- CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Immunomic Therapeutics, Inc.
Seasonal Allergic Rhinitis
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
- Trial name
- NCT01108783
- Testing
- Bilastine, Desloratadine
- Volunteers
- 720 people
- Sponsor
- Faes Farma, S.A.
Allergy
Safety of ALK Ragweed Tablet
This trial is performed to assess whether ALK Ragweed Tablet is safe to use in adults
- Trial name
- NCT00330083
- Testing
- ALK Ragweed Tablet
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinitis, Asthma
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
- Trial name
- NCT02061670
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Circassia Limited
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Hay Fever
Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM
gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this clinical trial is to confirm the safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM…
- Trial name
- NCT02156791
- Testing
- gpASIT+TM
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- BioTech Tools S.A.
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- MM09-SIT-023 (NCT04435990)
- Testing
- 10,000 MM09, 30,000 MM09
- Where
- 32 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Inmunotek S.L.
Allergy
A Study in Adults With Grass Pollen-induced Rhinoconjunctivitis
This is a 2 year clinical study to compare 5-grass mix SLIT-drops with placebo in relieving grass pollen-induced rhinoconjunctivitis symptoms and in use of symptom-relieving medication during the second grass pollen season (peak…
- Trial name
- Rhapsody (NCT04881461)
- Testing
- 5-grass mix SLIT-drops
- Where
- 48 sites in Czechia, Estonia and 4 more
- Volunteers
- 445 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinoconjunctivitis
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of this study is to determine whether the oral administration of grass pollen peptides is safe and effective in the treatment of allergic rhinitis.
- Trial name
- NCT00833066
- Testing
- gpASIT+TM
- Where
- 4 sites in Belgium
- Volunteers
- 54 people
- Sponsor
- BioTech Tools S.A.
Rhinitis, Allergic, Rhinoconjunctivitis, Allergic
HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human
The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without…
- Trial name
- NCT03758456
- Testing
- HAL-MRE1
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- HAL Allergy
Allergy
A Trial of the ALK Grass Tablet in Subjects With Hayfever
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
- Trial name
- NCT00227279
- Testing
- ALK Grass tablet
- Where
- Denmark
- Volunteers
- 634 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- NCT02557633
- Testing
- Grass MATA MPL 10200, Grass MATA MPL 18200
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Allergy Therapeutics
Allergy
A Trial of Grazax in Subjects With Hayfever
The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.
- Trial name
- NCT00421655
- Testing
- Grazax
- Where
- United States
- Volunteers
- 329 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH